Pfizer Halts Pursuit Of Zyvox Indication Based On Mortality Signal
Executive Summary
Pfizer will not pursue an indication for catheter-related infections for Zyvox (linezolid) after data from a Phase III trial indicated an increased risk of death among patients with the infections treated with the oxazolidinone antibiotic
You may also be interested in...
Zyvox is exceptional, PhRMA says
The Pharmaceutical Research and Manufacturers of America offers its first Clinical Trial Exceptional Service Award to Donald Batts (Michigan State University), Sharon Nachman (Stony Brook University) and Maryam Imam, an 11 year-old volunteer patient on March 14. The two researchers helped make advances in clinical trials that led to the development of Pfizer's Zyvox (linezolid) for treatment of drug-resistant bacterial infections...
Biohaven Shoots For Oral CGRP Leadership As Nurtec ODT Gains Momentum
The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.
Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: